<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511511</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2007-155</org_study_id>
    <secondary_id>EudraCT-number: 2007-002038-13</secondary_id>
    <nct_id>NCT00511511</nct_id>
  </id_info>
  <brief_title>Angiogenesis Inhibitors and Hypertension: Clinical Aspects</brief_title>
  <official_title>Angiogenesis Inhibitors and Hypertension: Clinical Aspects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to find simple clinical and laboratory parameters to predict the
      development of hypertension and to elucidate the mechanism of hypertension during treatment
      with the tyrosine kinase inhibitor Sunitinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhibition of angiogenesis with antibodies against vascular endothelial growth factor (VEGF)
      and VEGF receptor antagonists has become an established treatment for cancer. An
      unanticipated side effect of angiogenesis inhibitors is the development of hypertension. The
      pathogenesis of this hypertension is unknown. Not all patients will develop hypertension.
      However, it is not known which patient will and which patient will not develop hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hypertension</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women, with either renal cell carcinoma or gastro intestinal stromal tumors (GIST)
        intended to be treated solely with Sunitinib (single-agent treatment) and who are
        considered fit enough by their treating physician to receive Sunitinib
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, with either renal cell carcinoma or gastro intestinal stromal tumors
             (GIST) intended to be treated solely with Sunitinib (single-agent treatment) and who
             are considered fit enough by their treating physician to receive Sunitinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. H. van den Meiracker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol. 2005 Nov;17(6):578-83. Review.</citation>
    <PMID>16224236</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9.</citation>
    <PMID>15681523</PMID>
  </reference>
  <reference>
    <citation>Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006 Mar 20;24(9):1329-31. Epub 2006 Jan 30.</citation>
    <PMID>16446321</PMID>
  </reference>
  <reference>
    <citation>Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006 Mar 20;24(9):1363-9. Epub 2006 Jan 30.</citation>
    <PMID>16446323</PMID>
  </reference>
  <reference>
    <citation>Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007 Mar 13;115(10):1285-95. Review.</citation>
    <PMID>17353456</PMID>
  </reference>
  <reference>
    <citation>Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1500-5.</citation>
    <PMID>12231573</PMID>
  </reference>
  <reference>
    <citation>Bosnjak JJ, Terata K, Miura H, Sato A, Nicolosi AC, McDonald M, Manthei SA, Saito T, Hatoum OA, Gutterman DD. Mechanism of thrombin-induced vasodilation in human coronary arterioles. Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1080-6. Epub 2002 Dec 19.</citation>
    <PMID>12595282</PMID>
  </reference>
  <reference>
    <citation>Touyz RM. Regulation of endothelial nitric oxide synthase by thrombin. Hypertension. 2007 Mar;49(3):429-31. Epub 2007 Jan 8.</citation>
    <PMID>17210837</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669-76. Review.</citation>
    <PMID>12778165</PMID>
  </reference>
  <reference>
    <citation>Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003 Mar 18;107(10):1359-65.</citation>
    <PMID>12642354</PMID>
  </reference>
  <reference>
    <citation>Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998 Mar;274(3 Pt 2):H1054-8.</citation>
    <PMID>9530221</PMID>
  </reference>
  <reference>
    <citation>Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, Bunting S, de Vos AM, Jin H. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002 Jun;39(6):1095-100.</citation>
    <PMID>12052848</PMID>
  </reference>
  <reference>
    <citation>Broere A, Van Den Meiracker AH, Boomsma F, Derkx FH, Veld AJ, Schalekamp MA. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol. 1998 Dec;275(6 Pt 2):F870-7.</citation>
    <PMID>9843903</PMID>
  </reference>
  <reference>
    <citation>van der Linde NA, Boomsma F, van den Meiracker AH. Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens. 2005 May;23(5):1009-15.</citation>
    <PMID>15834287</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2010</last_update_posted>
  <keyword>hypertension</keyword>
  <keyword>angiogenesis inhibitors</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>Sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

